Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7	Substitute for	form 1449B	/PTO	Complete if Known		
	INFORMATIC	N DISCLO	SURE	Application Number	10/534,193	
	STATEMENT	BY APPLI	CANT	Filing Date	May 6, 2005	
				First Named Inventor	Hill et al.	
				Group Art Unit		
	(use as many sl	neets as ne	cessary)	Examiner Name		
Sheet	1	of	3	Attorney Docket Number	SPRUS1140 (026470-0501)	

U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent D	Ocument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Cite No. ¹	Number	Kind Code ² (if known)					

			FOREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
	A1	WO 95/15338	The University of Queensland	06-08-1995		4

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-iss publisher, city and/or country where published.		T ⁶					
	A2	CHEN et al., "Isolation, sequence analysis and characterization of a cDNA encoding human chaperonin 10" Biochim. Biophys. Acta, 1219, 189-190 (1994)	Will blade was to a to					
gar ere rene a renes e e entre e e entre e e entre e e	А3	COOKE et al., "LPS antagonism reduces graft-versus host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation." J. Clin. Invest., 107, 1581-1589 (2001)	-					
	A4	COOKE et al, "Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idoiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation." J. Immunol., 165, 6612-6619, (2000)						
	A5	COOKE et al, "An Experimental Model of Idiopathic Pneumonia Syndrome After Bone Marrow Transplantaion: I. The Roles of Minor H Antigens and Endotoxin." Blood, 88, 3230-3239 (1996)						
	A6	DICKSON et al., "Cloning, Expression, and Purification of a Functional Nonacetylated Mammallan Mitochondrial Chaperonin 10." J. Biol. Chem., 269, 26858-864, (1994)						
	A7	ELLIS et al., "Molecular Chaperones." Annu. Rev. Biochem. 60, 321-47, (1991)						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7	Substitute for form	1449B/	PTO		Complete if Known		
	INFORMATION DI	SCLO	SURE	Application Number	10/534,193		
	STATEMENT BY A	APPLI	CANT	Filing Date	May 6, 2005		
				First Named Inventor	Hill et al.		
				Group Art Unit			
	(use as many sheets	as ne	cessary)	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	SPRUS1140 (026470-0501)		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1					
	A8	HARTMAN et al., "Identification of a mammalian 10-kDa heat shock protein, a mitochondrial chaperonin 10 homologue essential for assisted folding of trimeric ornithine transcarbamoylase <i>in vitro</i> ." Proc. Natl. Acad. Sci. USA, 89, 3394-8, (1992)	T - CONT. (MAX. AMA. A. A. A.			
	A9	HILL et al., "Interleukin-11 Promotes T Cell Polarization and Prevents Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation." J. Clin. Invest., 102, 115-123 (1998)				
	A10	HILL et al., "Total Body Irradiation and Acute Graft-Versus-Host disease: The role of Gastrointestinal Damage and Inflammatory Cytokines." Blood, 90, 3204-3213, (1997)				
· an and a · a · a · a · a · a · a · a · a · a	A11	HILL et al, "Differential roles of IL-1 and TNF- α on graft-versus-host disease and graft versus leukemia." J. Clin. Invest., 104, 459-467, (1999)				
	A12	KRIJANOVSKI et al, "Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease." Blood, 94, 825-831, (1999)	*			
	A13	MORTON et al., "Immunosuppression detected in pregnant mice by rosette inhibition test." Nature, 249; 459-460, (1974)	4			
	A14	MORTON et al., "Studies of the Rosette Inhibition Test in Pregnant Mice: Evidence of Immunosuppression?" Proc. R. Soc. Lond., 193; 413-9, (1976)				
	A15	MORTON et al., "Recent Advances in Mammalian Development." Current Topics in Developmental Biology, 23; 73-92 (1987)				

Examiner	Date	The state of the s
Signature	Considered	PRODUCTION I ILL

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.